

# Alan Winston

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5194872/publications.pdf>

Version: 2024-02-01

97  
papers

2,864  
citations

186209

28  
h-index

197736

49  
g-index

99  
all docs

99  
docs citations

99  
times ranked

4033  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Controversies in HIV-associated neurocognitive disorders. <i>Lancet Neurology</i> , The, 2014, 13, 1139-1151.   | 4.9 | 242       |
| 2  | Increased brain-predicted aging in treated HIV disease. <i>Neurology</i> , 2017, 88, 1349-1357.   | 1.5 | 200       |
| 3  | Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. <i>Lancet HIV</i> , the, 2021, 8, e474-e485.   | 2.1 | 190       |
| 4  | Neuroinflammation in treated HIV-positive individuals. <i>Neurology</i> , 2016, 86, 1425-1432.  | 1.5 | 136       |
| 5  | Transmission of monkeypox virus through sexual contact – A novel route of infection. <i>Journal of Infection</i> , 2022, 85, 334-363.   | 1.7 | 117       |
| 6  | 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0. <i>HIV Medicine</i> , 2020, 21, 617-624.   | 1.0 | 115       |
| 7  | Does Choice of Combination Antiretroviral Therapy (cART) Alter Changes in Cerebral Function Testing after 48 Weeks in Treatment-naïve, HIV-1 Infected Individuals Commencing cART? A Randomized, Controlled Study. <i>Clinical Infectious Diseases</i> , 2010, 50, 920-929. | 2.9 | 113       |
| 8  | Could antiretroviral neurotoxicity play a role in the pathogenesis of cognitive impairment in treated HIV disease?. <i>Aids</i> , 2015, 29, 253-261.  | 1.0 | 113       |
| 9  | Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial. <i>EClinicalMedicine</i> , 2022, 44, 101262.  | 3.2 | 87        |
| 10 | Cognitive disorders in people living with HIV. <i>Lancet HIV</i> , the, 2020, 7, e504-e513.   | 2.1 | 78        |
| 11 | Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV-positive persons version 9.0. <i>HIV Medicine</i> , 2018, 19, 309-315.   | 1.0 | 77        |
| 12 | Low Rates of Neurocognitive Impairment Are Observed in Neuro-Asymptomatic HIV-Infected Subjects on Effective Antiretroviral Therapy. <i>HIV Clinical Trials</i> , 2011, 12, 333-338.  | 2.0 | 67        |
| 13 | Adjudicated Morbidity and Mortality Outcomes by Age among Individuals with HIV Infection on Suppressive Antiretroviral Therapy. <i>PLoS ONE</i> , 2014, 9, e95061.  | 1.1 | 67        |
| 14 | Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials. <i>HIV Medicine</i> , 2016, 17, 358-367.   | 1.0 | 61        |
| 15 | Defining cognitive impairment in people-living-with-HIV: the POPPY study. <i>BMC Infectious Diseases</i> , 2016, 16, 617.   | 1.3 | 61        |
| 16 | Neurocognitive Function in HIV Infected Patients on Antiretroviral Therapy. <i>PLoS ONE</i> , 2013, 8, e61949.  | 1.1 | 58        |
| 17 | Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021. <i>HIV Medicine</i> , 2022, 23, 849-858.   | 1.0 | 57        |
| 18 | Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study. <i>Lancet HIV</i> , the, 2017, 4, e295-e302.  | 2.1 | 47        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | Pain in people living with HIV and its association with healthcare resource use, well being and functional status. <i>Aids</i> , 2018, 32, 2697-2706.   | 1.0 | 47        |
| 20 | Correlation between CSF and blood neurofilament light chain protein: a systematic review and meta-analysis. <i>BMJ Neurology Open</i> , 2021, 3, e000143.   | 0.7 | 46        |
| 21 | Tryptophan Metabolism and Its Relationship with Depression and Cognitive Impairment among HIV-infected Individuals. <i>International Journal of Tryptophan Research</i> , 2016, 9, IJTR.S36464.   | 1.0 | 42        |
| 22 | Neuropsychiatric Adverse Events With Ritonavir-Boosted Darunavir Monotherapy in HIV-Infected Individuals: A Randomised Prospective Study. <i>HIV Clinical Trials</i> , 2010, 11, 163-169.   | 2.0 | 39        |
| 23 | Moving on From HAND: Why We Need New Criteria for Cognitive Impairment in Persons Living With Human Immunodeficiency Virus and a Proposed Way Forward. <i>Clinical Infectious Diseases</i> , 2021, 73, 1113-1118.   | 2.9 | 39        |
| 24 | Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study. <i>HIV Medicine</i> , 2012, 13, 245-251.   | 1.0 | 35        |
| 25 | Terminal differentiation of T cells is strongly associated with CMV infection and increased in HIV-positive individuals on ART and lifestyle matched controls. <i>PLoS ONE</i> , 2017, 12, e0183357.  | 1.1 | 34        |
| 26 | Cohort profile: The Pharmacokinetic and clinical Observations in PeoPle over fifty (POPPY) study. <i>International Journal of Epidemiology</i> , 2018, 47, 1391-1392e.  | 0.9 | 33        |
| 27 | Medicalising normality? Using a simulated dataset to assess the performance of different diagnostic criteria of HIV-associated cognitive impairment. <i>PLoS ONE</i> , 2018, 13, e0194760.  | 1.1 | 32        |
| 28 | Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1354-9.  | 1.3 | 30        |
| 29 | Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1642-1647.  | 1.3 | 29        |
| 30 | Depression, lifestyle factors and cognitive function in people living with HIV and comparable negative controls. <i>HIV Medicine</i> , 2019, 20, 274-285.   | 1.0 | 28        |
| 31 | Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. <i>JCI Insight</i> , 2022, 7, .  | 2.3 | 26        |
| 32 | Does acute hepatitis C infection affect the central nervous system in HIV-1 infected individuals?. <i>Journal of Viral Hepatitis</i> , 2009, 17, 419-426.   | 1.0 | 24        |
| 33 | CSF/plasma HIV-1 RNA discordance even at low levels is associated with up-regulation of host inflammatory mediators in CSF. <i>Cytokine</i> , 2016, 83, 139-146.  | 1.4 | 22        |
| 34 | Sleep Disorders in Human Immunodeficiency Virus: A Substudy of the Pharmacokinetics and Clinical Observations in People Over Fifty (POPPY) Study. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofaa561.   | 0.4 | 20        |
| 35 | Risk factors and impact of patterns of co-occurring comorbidities in people living with HIV. <i>Aids</i> , 2019, 33, 1871-1880.   | 1.0 | 18        |
| 36 | CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies. <i>Clinical Infectious Diseases</i> , 2021, 73, 50-59. | 2.9 | 18        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | High Cellular Monocyte Activation in People Living With Human Immunodeficiency Virus on Combination Antiretroviral Therapy and Lifestyle-Matched Controls Is Associated With Greater Inflammation in Cerebrospinal Fluid. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx108. | 0.4 | 17        |
| 38 | Cardiovascular disease in women living with HIV: A narrative review. <i>Maturitas</i> , 2018, 108, 58-70.  | 1.0 | 16        |
| 39 | No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts. <i>Aids</i> , 2018, 32, 985-997.  | 1.0 | 15        |
| 40 | Self-management Interventions for Pain and Physical Symptoms Among People Living With HIV: A Systematic Review of the Evidence. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 79, 206-225.   | 0.9 | 15        |
| 41 | Level of agreement between frequently used cardiovascular risk calculators in people living with HIV. <i>HIV Medicine</i> , 2019, 20, 347-352.   | 1.0 | 14        |
| 42 | Chronic Kidney Disease Risk in African and Caribbean Populations With HIV. <i>Journal of Infectious Diseases</i> , 2018, 218, 1767-1772.   | 1.9 | 13        |
| 43 | Magnetic Resonance Imaging of Cerebral Small Vessel Disease in Men Living with HIV and HIV-Negative Men Aged 50 and Above. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 453-460.  | 0.5 | 13        |
| 44 | Two patterns of cerebral metabolite abnormalities are detected on proton magnetic resonance spectroscopy in HIV-infected subjects commencing antiretroviral therapy. <i>Neuroradiology</i> , 2012, 54, 1331-1339.  | 1.1 | 11        |
| 45 | Differences in the Direction of Change of Cerebral Function Parameters Are Evident over Three Years in HIV-Infected Individuals Electively Commencing Initial cART. <i>PLoS ONE</i> , 2015, 10, e0118608.  | 1.1 | 11        |
| 46 | Host, disease, and antiretroviral factors are associated with normalization of the CD4:CD8 ratio after initiating antiretroviral therapy. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 1682-1685.e1.   | 1.5 | 11        |
| 47 | Cognitive Impairment in a Clinical Setting. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, e10-e13.   | 0.9 | 11        |
| 48 | Responses to Quadrivalent Influenza Vaccine Reveal Distinct Circulating CD4+CXCR5+ T Cell Subsets in Men Living with HIV. <i>Scientific Reports</i> , 2019, 9, 15650.  | 1.6 | 11        |
| 49 | Tryptophan metabolism and its relationship with central nervous system toxicity in people living with HIV switching from efavirenz to dolutegravir. <i>Journal of NeuroVirology</i> , 2019, 25, 85-90.   | 1.0 | 11        |
| 50 | Can antiretroviral therapy prevent HIV-associated cognitive disorders?. <i>Current Opinion in HIV and AIDS</i> , 2014, 9, 11-16.   | 1.5 | 10        |
| 51 | An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2075-2082.   | 1.3 | 10        |
| 52 | Sleep health and cognitive function among people with and without HIV: the use of different machine learning approaches. <i>Sleep</i> , 2021, 44, .  | 0.6 | 10        |
| 53 | Non-nucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy is associated with lower cell-associated HIV RNA and DNA levels compared to protease inhibitor-based therapy. <i>ELife</i> , 2021, 10, .   | 2.8 | 10        |
| 54 | Developing a Bayesian adaptive design for a phase I clinical trial: a case study for a novel HIV treatment. <i>Statistics in Medicine</i> , 2017, 36, 754-771.   | 0.8 | 9         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | The predictors of pain extent in people living with HIV. <i>Aids</i> , 2020, 34, 2071-2079.   | 1.0 | 9         |
| 56 | Changes in functional connectivity in people with HIV switching antiretroviral therapy. <i>Journal of NeuroVirology</i> , 2020, 26, 754-763.  | 1.0 | 9         |
| 57 | Agreement between self-reported and objective measures of sleep in people with HIV and lifestyle-similar HIV-negative individuals. <i>Aids</i> , 2021, 35, 1051-1060.   | 1.0 | 9         |
| 58 | Mortality and AIDS-defining events among young people following transition from paediatric to adult HIV care in the UK. <i>HIV Medicine</i> , 2021, 22, 631-640.  | 1.0 | 9         |
| 59 | Correlation between cerebrospinal fluid and plasma neurofilament light protein in treated HIV infection: results from the COBRA study. <i>Journal of NeuroVirology</i> , 2022, 28, 54-63.   | 1.0 | 9         |
| 60 | Evolution of changes in cognitive function after the initiation of antiretroviral therapy. <i>AIDS Research and Therapy</i> , 2016, 13, 20.   | 0.7 | 8         |
| 61 | A first-in-human study of the novel HIV-fusion inhibitor C34-PEG4-Chol. <i>Scientific Reports</i> , 2017, 7, 9447.  | 1.6 | 8         |
| 62 | Factors associated with obesity in the Pharmacokinetic and Clinical Observations in People over Fifty (POPPY) cohort: an observational cross-sectional analysis. <i>HIV Medicine</i> , 2020, 21, 441-452.   | 1.0 | 8         |
| 63 | The symptomatology of cerebrospinal fluid HIV RNA escape: a large case-series. <i>Aids</i> , 2021, 35, 2341-2346.   | 1.0 | 8         |
| 64 | Neurocognitive Function in HIV-Infected Patients: Comparison of Two Methods to Define Impairment. <i>PLoS ONE</i> , 2014, 9, e103498.   | 1.1 | 7         |
| 65 | Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy. <i>HIV Medicine</i> , 2016, 17, 471-478.   | 1.0 | 7         |
| 66 | Changes in Cognitive Function Over 96 Weeks in Naive Patients Randomized to Darunavir-Ritonavir Plus Either Raltegravir or Tenofovir-Emtricitabine. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2017, 74, 185-192.  | 0.9 | 7         |
| 67 | Measurement of Retinal Vessels as a Biomarker of Cerebrovascular Aging in Older HIV-Positive Men Compared With Controls. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 199-205.   | 0.9 | 7         |
| 68 | Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 628-639. | 1.3 | 7         |
| 69 | Comorbidity indices in people with HIV and considerations for coronavirus disease 2019 outcomes. <i>Aids</i> , 2020, 34, 1795-1800.   | 1.0 | 7         |
| 70 | Respiratory symptoms and chronic bronchitis in people with and without HIV infection. <i>HIV Medicine</i> , 2021, 22, 11-21.  | 1.0 | 7         |
| 71 | Clinical application of the inhibitory quotient: is there a role in HIV protease inhibitor therapy?. <i>Current Opinion in HIV and AIDS</i> , 2008, 3, 608-611.   | 1.5 | 6         |
| 72 | HIV-1 CNS in vitro infectivity models based on clinical CSF samples. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 235-243.  | 1.3 | 6         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Objective and subjective rapid frailty screening tools in people with HIV. <i>HIV Medicine</i> , 2021, 22, 146-150.  | 1.0 | 6         |
| 74 | The clinical pharmacology of antiretrovirals in development. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2006, 2, 447-458.   | 1.5 | 5         |
| 75 | 48-week efficacy and safety of transitioning virologically stable HIV-1 patients from nevirapine IR 200 mg BID to nevirapine XR 400 mg QD (TRANxITION). <i>Journal of the International AIDS Society</i> , 2010, 13, P45.                      | 1.2 | 5         |
| 76 | Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1041-1045.           | 1.3 | 5         |
| 77 | Cerebrospinal-fluid exposure of efavirenz and its major metabolites when dosed at 400 and 600 mg once daily; a randomized controlled trial. <i>Journal of the International AIDS Society</i> , 2014, 17, 19541.                                | 1.2 | 4         |
| 78 | Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach. <i>Journal of the International AIDS Society</i> , 2014, 17, 19586.                        | 1.2 | 4         |
| 79 | Predictive value of neurological symptoms in persons with suspected neurosyphilis. <i>Sexually Transmitted Infections</i> , 2022, 98, 228-229.   | 0.8 | 4         |
| 80 | Clinical research cerebral MRI findings in HIV-positive subjects and appropriate controls. <i>Aids</i> , 2018, 32, 2077-2081.  | 1.0 | 4         |
| 81 | Brain Perfusion, Regional Volumes, and Cognitive Function in Human Immunodeficiency Virus-positive Patients Treated With Protease Inhibitor Monotherapy. <i>Clinical Infectious Diseases</i> , 2019, 68, 1031-1040.                            | 2.9 | 3         |
| 82 | Cerebrospinal fluid exposure of cenicriviroc in HIV-positive individuals with cognitive impairment. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1039-1040.   | 1.1 | 3         |
| 83 | “I have failed to separate my HIV from this pain”: the challenge of managing chronic pain among people with HIV. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, , 1-9.   | 0.6 | 3         |
| 84 | Associations between plasma nucleoside reverse transcriptase inhibitors concentrations and cognitive function in people with HIV. <i>PLoS ONE</i> , 2021, 16, e0253861.  | 1.1 | 3         |
| 85 | A Phase I study to assess the safety, tolerability and pharmacokinetic profile of boceprevir and sildenafil when dosed separately and together, in healthy male volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 1812-5.   | 1.3 | 2         |
| 86 | Molecular neuroimaging of inflammation in HIV. <i>Clinical and Experimental Immunology</i> , 2022, 210, 14-23.   | 1.1 | 2         |
| 87 | Drug treatment for adults with HIV infection. <i>BMJ</i> , The, 2015, 350, h1555-h1555.  | 3.0 | 1         |
| 88 | Neuropharmacology. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 152, 55-64.   | 1.0 | 1         |
| 89 | The development and validation of a novel LC-MS/MS method for the quantification of cenicriviroc in human plasma and cerebrospinal fluid. <i>Biomedical Chromatography</i> , 2020, 34, e4711.  | 0.8 | 1         |
| 90 | Response to: “How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population?” <sup>TM</sup> . <i>HIV Medicine</i> , 2020, 21, e17-e18. | 1.0 | 1         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 91 | Plasma nucleotide reverse transcriptase inhibitor concentration and their associations with liver and renal parameters in people living with HIV. <i>Aids</i> , 2020, 34, 790-793.                             | 1.0 | 1         |
| 92 | No evidence of neuronal damage as measured by neurofilament light chain in a HIV cure study utilising a kick-and-kill approach. <i>Journal of Virus Eradication</i> , 2021, 7, 100056.                         | 0.3 | 1         |
| 93 | Correlation between computerised and standard cognitive testing in people with HIV and HIV-negative individuals. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2021, 33, 1296-1307. | 0.6 | 1         |
| 94 | Changes in cerebral function parameters in HIV-1 infected subjects undergoing a treatment simplification to darunavir/ritonavir. <i>Journal of the International AIDS Society</i> , 2010, 13, P52-P52.         | 1.2 | 0         |
| 95 | Overestimation or Underestimation of Neurocognitive Impairment in HIV-Infected Cohorts?. <i>HIV Clinical Trials</i> , 2012, 13, 299-300.   | 2.0 | 0         |
| 96 | Response to: Asymptomatic neurocognitive impairment is a risk for symptomatic decline over a 3-year study period. <i>Aids</i> , 2021, 35, 1152-1153.   | 1.0 | 0         |
| 97 | Cerebral function parameters in people with HIV switching integrase inhibitors: a randomized controlled trial. <i>HIV Research and Clinical Practice</i> , 2021, , 1-9.  | 1.1 | 0         |